Bausch + Lomb expands eye-care portfolio with J&J’s Blink

Johnson & Johnson

Bausch + Lomb expands eye-care portfolio with J&J’s Blink

July 6 (Reuters) – Bausch + Lomb (BLCO.TO) said on Thursday it has acquired Johnson & Johnson’s (JNJ.N) eye and contact lens drops for $106.5 million in an all-cash deal to expand its portfolio of over-the-counter eye care products.

This comes after the company struck a $1.75 billion deal with Swiss drugmaker Novartis (NOVN.S) late last month to buy several eye-care products including anti-inflammation eye drop Xiidra.

Reporting by Mariam Sunny in Bengaluru; Editing by Dhanya Ann Thoppil and Savio D’Souza
 
Source: Reuters
/by
You might also like
GlaxoSmithKlineGSK makes $2B play to challenge Merck in chronic cough market
Johnson & JohnsonJ&J sues in latest bid to halt Medicare drug price negotiations
Johnson & JohnsonReutersJ&J starts share exchange offer for consumer health spin-off Kenvue
Johnson & JohnsonJ&J unit wins $59.4 million verdict in veterinary implant patent trial
BiogenBiogen in up to $1.8 bln deal as rare diseases take center stage
U.S. FDA approves J&J’s chemotherapy-free treatment for lung cancer
J&JJ&J says drug combo contains lung cancer from spreading for longer duration
Novo NordiskNovo Nordisk shells out $1.1B for Forma, sickle cell drug